The effect of esketamine combined with pregabalin on chronic pain after breast cancer surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038124

Enrollment

Unknown

Registered

2020-09-11

Start date

2020-09-15

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic postsurgical pain

Interventions

Group C:placebo capsules +normal saline

Group EP:Esketamine combined with pregabalin

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients undergoing elecitve laparoscopic hysterectomy; 2) Aged 18 to 80 years; 3) Body mass index was 15~30 kg/m2; 4) The American Society of Anesthesiologists (ASA) classification is I ~ III level.

Exclusion criteria

Exclusion criteria: 1) severe heart and lung disease; 2) hepatic and renal insufficiency; 3) chronic pain disease; 4) mental illness.

Design outcomes

Primary

Measure	Time frame
incidence of chronic postsurgical pain at 3 and 6 months;	—

Secondary

Measure	Time frame
Oxycodone consumption for first 48 h postoperatively;NRS scores at different time after surgery;Postoperative adverse effects;	—

Countries

China

Contacts

Public ContactQing-ren Liu

Wuxi Xishan People's Hospital

Liuqr5250@163.com+86 13601510412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026